Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)

Published:2017-07-31 Issue:6 Volume:12 Page:833-838
ISSN:1776-2596
Container-title:Targeted Oncology
language:en
Short-container-title:Targ Oncol

Author:

Auliac Jean-Bernard,Monnet Isabelle,Dubos-Arvis Catherine,Chiappa Anne Marie,Baize Nathalie,Bota Suzana,Vergnenegre Alain,Doubre Helene,Locher Chrystele,Bizieux Acya,Robinet Gilles,Chouaid Christos

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Oncology

Link

http://link.springer.com/article/10.1007/s11523-017-0520-7/fulltext.html

Reference25 articles.

1. World Health Organization (WHO). Cancer. Fact sheet no. 297. http://www.who.int/mediacentre/factsheets/fs297/en/ .

2. Barlesi F, Mazières J, Merlio JP, et al. Biomarkers France contributors. Routine molecular profiling of patients with advanced non–small-cell lung cancer: Results of a 1-year nationwide programme of the French cooperative thoracic intergroup (IFCT). Lancet. 2016;387:1415–26.

3. Soda M, Choi YL, Enomoto M. Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448:561–6.

4. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med. 2010;363:1693–703.

5. Shaw AT, Kim D-W, Nakagawa K, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368:2385–94.

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Real-World Treatment and Outcomes in ALK-Rearranged NSCLC: Results From a Large U.S.-Based Database;JTO Clinical and Research Reports;2024-08

2. A multicenter, retrospective archive study of radiological and clinical features of ALK-positive non-small cell lung cancer patients and crizotinib efficacy;Medicine;2024-05-24

3. Matching-Adjusted Indirect Comparisons of Lorlatinib Versus Chemotherapy for Patients With Second-Line or Later Anaplastic Lymphoma Kinase–Positive Non–Small Cell Lung Cancer;Value in Health;2023-01

4. High Tumor Mutation Burden and DNA Repair Gene Mutations are Associated with Primary Resistance to Crizotinib in ALK-Rearranged Lung Cancer;OncoTargets and Therapy;2021-09

5. The Cost-Effectiveness of Lorlatinib Versus Chemotherapy as a Second- or Third-Line Treatment in Anaplastic Lymphoma Kinase (ALK)-Positive Non-small-cell Lung Cancer in Sweden;PharmacoEconomics;2021-06-03